Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02792465
Recruitment Status : Recruiting
First Posted : June 7, 2016
Last Update Posted : January 26, 2021
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
This is a phase 1 study of investigational agent CFI-402257 in patients with advanced cancer. The purpose of this study is to see how safe and tolerable CFI-402257 is in cancer patients as well as the pharmacokinetics (PK). This study is the first time that CFI-402257 is given to humans.

Condition or disease Intervention/treatment Phase
Advanced Solid Cancers Breast Cancer Drug: CFI-402257 Drug: Fulvestrant Phase 1

Detailed Description:

CFI-402257 is an oral drug that blocks TTK protein kinase (also known as Monopolar spindle 1 [Mps1]) activity. TTK is a protein that is important in regulating cell growth, and cell death, and ensuring proper division. Many tumors are shown to make too much TTK. When there is too much TTK produced, it is believed to contribute to uncontrolled cancer cell growth and division leading to additional mutations in cancer cells. Therefore, it is believed that blocking this protein from working will lead to cancer cell death, stopping tumors from growing or shrinking them.

This study has two parts: dose escalation and dose expansion.

The dose escalation part tested different dose levels of study drug in groups of patients to find the highest dose of study drug that can be given safely to patients (called maximum tolerated dose or MTD). This part of the study is now complete.

The expansion part will further assess the safety, tolerability, and PK of the MTD found in the escalation part of the study in additional group of patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Cohort A: Patients with advanced cancer. Treatment: Daily dose of 168 mg of CFI 402257.

Cohort B: Patients with advanced breast cancer Treatment: Daily dose of 168 mg of CFI 402257.

Cohort C: Patients with breast cancer tested positive for ER and/or PR, and HER2-negative. Treatment: Daily dose of 168 mg of CFI 402257 + Fulvestrant (standard hormonal treatment) on Day 1 and 15 of each 28 day cycle

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors
Actual Study Start Date : November 11, 2016
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Fulvestrant

Arm Intervention/treatment
Experimental: Cohort A
CFI-402257 capsules will be taken orally, once a day, every day.
Drug: CFI-402257
Experimental: Cohort B
CFI-402257 capsules will be taken orally, once a day, every day.
Drug: CFI-402257
Experimental: Cohort C
CFI-402257 capsules will be taken orally, once a day, every day + Fulvestrant injection on day 1 and day 15 of every 28 day cycle
Drug: CFI-402257
Drug: Fulvestrant



Primary Outcome Measures :
  1. Highest dose level that does not lead to unacceptable toxicity in two or more patients in a dosing cohort [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (AEs) graded according to NCI CTCAE v4.03 [ Time Frame: 2 years ]
  2. Treatment-emergent changes in vital signs [ Time Frame: 2 years ]
  3. Treatment-emergent changes in clinical laboratory tests from baseline values obtained prior to treatment [ Time Frame: 2 years ]
  4. Treatment-emergent changes in physical examinations, ECOG performance status, electrocardiograms (ECGs), at periodic intervals during the study and at End of Treatment [ Time Frame: 2 years ]
  5. Area under the plasma concentration-time curve (AUC) [ Time Frame: 2 years ]
  6. Elimination half-life (T½) [ Time Frame: 2 years ]
  7. Maximum plasma concentration (Cmax) [ Time Frame: 2 years ]
  8. Minimum plasma concentration (Cmin) [ Time Frame: 2 years ]
  9. Time when Cmax occurs (Tmax) [ Time Frame: 2 years ]
  10. Average plasma concentration at steady state (Cavg) [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria - Cohort A:

  • Have histological or cytological proof of advanced cancer that has progressed and for which there is no further standard anticancer therapy available in the opinion of the Investigator.
  • Patients must have measurable disease as per RECIST v 1.1 guidelines.
  • Patients must be ≥18 years of age.
  • Have clinically acceptable laboratory screening results (i.e., clinical chemistry, hematology, and urinalysis) within certain limits.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Be able to swallow oral medications.
  • Have a life expectancy of greater than 3 months.
  • Women and men of child-producing potential must agree to use highly effective means of contraception for a specified period.
  • A negative serum pregnancy test for women of childbearing potential.
  • Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, provide archived tissue if available for biomarker studies, provide a blood sample for genetic testing and agree to return for the required assessments.

Inclusion Criteria - Cohort B:

  • Have histologically and/or cytologically confirmed diagnosis of breast cancer that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
  • Patients must have had at least 1 but not more than 4 prior lines of cytotoxic chemotherapy for breast cancer in the advanced/metastatic setting, and must have had prior treatment with an anthracycline and a taxane (unless contraindicated) in either the neo/adjuvant or metastatic setting.
  • Patients must have measurable disease as per RECIST v 1.1 guidelines.
  • Patients must be female.
  • Patients must be ≥18 years of age.
  • Have clinically acceptable laboratory screening results (i.e., clinical chemistry, hematology, and urinalysis) within certain limits.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Be able to swallow oral medications.
  • Have a life expectancy of greater than 3 months.
  • Women of child-producing potential must agree to use highly effective means of contraception for a specified period.
  • A negative serum pregnancy test for women of childbearing potential.
  • Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, provide archived tissue if available for biomarker studies, provide a blood sample for genetic testing and agree to return for the required assessments.

Inclusion criteria - Cohort C:

  • Have histological or cytological confirmed diagnosis of breast cancer positive for ER and/or PR and negative for HER2 by ASCO/CAP criteria, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists.
  • Patients must have had prior treatment with an aromatase inhibitor in combination with CDK4/6 inhibitor, for a duration of not less than 12 months prior to disease progression. Up to 1 line of cytotoxine chemotherapy in the metastatic setting is allowed.
  • Patients must have measurable disease as per RECIST v 1.1 guidelines.
  • Patients must be female.
  • Patients must be ≥18 years of age.
  • Patients are post-menopausal (including use of ovarian function suppression with LHRH agonist)
  • Have clinically acceptable laboratory screening results (i.e., clinical chemistry, hematology, and urinalysis) within certain limits.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Be able to swallow oral medications.
  • Have a life expectancy of greater than 3 months.
  • Women of child-producing potential must agree to use highly effective means of contraception for a specified period.
  • A negative serum pregnancy test for women of childbearing potential.
  • Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, provide archived tissue if available for biomarker studies, provide a blood sample for genetic testing and agree to return for the required assessments.

Exclusion Criteria (all cohorts):

  • Women who are pregnant or nursing.
  • Have received radiotherapy (patients having limited field palliative radiotherapy less than 2 weeks), chemotherapy, biological therapy, or investigational treatment less than four weeks (six weeks for nitrosoureas or mitomycin C) prior to first dose of study drug or have not recovered from all acute toxicities from prior treatments and those deemed by the Investigator not to affect safety assessment.
  • Patients who have received growth factors within 14 days prior to initiation of dosing of CFI-402257 or who will require ongoing treatment with growth factors throughout the duration of the trial.
  • Have active, acute, or clinically significant chronic infections.
  • Have uncontrolled severe hypertension.
  • Have symptomatic congestive heart failure.
  • Have active angina pectoris or recent myocardial infarction (within 6 months).
  • Have chronic atrial fibrillation or QTc of greater than 470 msec.
  • Have had major surgery within 21 days of starting therapy.
  • Have additional uncontrolled serious medical or psychiatric illness.
  • Have any medical condition that would impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting.
  • Known central nervous system metastasis.
  • Patients being treated with full dose warfarin are excluded.
  • Patients being treated with the following drugs are excluded: Alfentanil, Pimozide, Cyclosporine, Quinidine, Digoxin, Sirolimus, Dihydroergotamine, Tacrolimus, Ergotamine, Warfarin, Fentanyl.
  • Patient who have had prior treatment with a TTK/MPS1 inhibitor
  • For Expanded Cohort C - have previously been treated with, or have a contraindication to treatment with fulvestrant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02792465


Contacts
Layout table for location contacts
Contact: Philippe Bedard, M.D. 416-946-4534

Locations
Layout table for location information
Canada, British Columbia
BC Cancer Agency Recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Contact: Daniel Renouf, M.D.    (604) 877-6000      
Principal Investigator: Daniel Renouf, M.D.         
Canada, Ontario
The Ottawa Hospital Cancer Centre Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: John Hilton, M.D.    (613) 737-7700      
Principal Investigator: John Hilton, M.D.         
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Philippe Bedard, M.D.    (416) 946-4534      
Principal Investigator: Philippe Bedard, M.D.         
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Layout table for investigator information
Principal Investigator: Philippe Bedard, M.D. Princess Margaret Cancer Centre
Layout table for additonal information
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT02792465    
Other Study ID Numbers: CFI-402257-CL-001
First Posted: June 7, 2016    Key Record Dates
Last Update Posted: January 26, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fulvestrant
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs